Drug Profile
M 9831
Alternative Names: M9831; VX 984Latest Information Update: 21 Aug 2023
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Developer Merck KGaA
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 21 Aug 2023 Chemical structure information added
- 04 Jan 2023 Phase I development is still ongoing for Solid tumours in USA (PO) (Vertex Pharmaceuticals pipeline, January 2023)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)